Renal carcinoma cells express Membrane Type 1-Matrix
Metalloproteinase (MT1-MMP, MMP-14) to degrade extracellular matrix components and a range of bioactive molecules to allow
metastasis and cell proliferation. The activity of
MT1-MMP is modulated by the endogenous inhibitors,
Tissue Inhibitor of Metalloproteinases (TIMPs). In this study, we describe a novel strategy that would enable a "designer"
TIMP-1 tailored specifically for
MT1-MMP inhibition (V4A/P6V/T98L; Kiapp 1.66 nM) to be targeted to the plasma membrane for more effective
MT1-MMP inhibition. To achieve this, we fuse the designer
TIMP-1 to the glycosyl-
phosphatidyl inositol (GPI) anchor of the
prion protein to create a membrane-tethered, high-affinity TIMP variant named "T1Pr αMT1" that is predominantly located on the cell surface and co-localised with
MT1-MMP. Confocal microscopy shows that T1Pr αMT1 is found throughout the cell surface in particular the membrane ruffles where
MT1-MMP is most abundant. Expression of T1Pr αMT1 brings about a complete abrogation of the gelatinolytic activity of cellular
MT1-MMP in HT1080
fibrosarcoma cells whilst in
renal carcinoma cells CaKi-1, the GPI-TIMP causes a disruption in
MMP-mediated proteolysis of ECM components such as
fibronectin,
collagen I and
laminin that consequently triggers a downstream senescence response. Moreover, the transduced cells also suffer from an impairment in proliferation and survival in vitro as well as in NOD/SCID mouse xenograft. Taken together, our findings demonstrate that the GPI anchor of
prion could be exploited as a targeting device in TIMP engineering for
MT1-MMP inhibition with a potential in
renal carcinoma therapy.